Targeting EGFR and PI3K pathways in ovarian cancer

201367 citationsJournal Articlehybrid Open Access

Authors

Sharon Glaysher · Queen Alexandra Hospital

Louise Bolton · Queen Alexandra Hospital

Peter Johnson · Queen Alexandra Hospital

Neil Atkey · Sheffield Children's NHS Foundation Trust

Michael J. Dyson · Sheffield Children's NHS Foundation Trust

C Torrance · Horizon Discovery Group (United Kingdom)

Ian A. Cree

Abstract

Phase I/II clinical trials with these agents should include further pharmacodynamic endpoints and molecular characterisation to identify patients most likely to benefit from this strategy.

Topics & Keywords

PI3K/AKT/mTOR signaling in cancer Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 109, Issue 7, pp. 1786-1794

DOI: 10.1038/bjc.2013.529

Field-Weighted Citation Impact: 3.89